Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) FCF Margin: 2020-2025

Historic FCF Margin for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to -2,135.38%.

  • Insight Molecular Diagnostics' FCF Margin rose 274896.00% to -2,135.38% in Q3 2025 from the same period last year, while for Sep 2025 it was -543.71%, marking a year-over-year increase of 232343.00%. This contributed to the annual value of -1,128.60% for FY2024, which is 44199.00% up from last year.
  • As of Q3 2025, Insight Molecular Diagnostics' FCF Margin stood at -2,135.38%, which was down 66.89% from -1,279.54% recorded in Q2 2025.
  • Insight Molecular Diagnostics' 5-year FCF Margin high stood at -208.02% for Q4 2021, and its period low was -18,291.04% during Q3 2022.
  • Moreover, its 3-year median value for FCF Margin was -1,492.99% (2023), whereas its average is -2,145.05%.
  • In the last 5 years, Insight Molecular Diagnostics' FCF Margin skyrocketed by 4,226,259bps in 2021 and then plummeted by 1,713,820bps in 2022.
  • Quarterly analysis of 5 years shows Insight Molecular Diagnostics' FCF Margin stood at -208.02% in 2021, then crashed by 360,584bps to -3,813.87% in 2022, then spiked by 232,087bps to -1,492.99% in 2023, then spiked by 111,688bps to -376.11% in 2024, then surged by 274,896bps to -2,135.38% in 2025.
  • Its FCF Margin was -2,135.38% in Q3 2025, compared to -1,279.54% in Q2 2025 and -288.35% in Q1 2025.